Assembly Bio Reports Reduced Net Loss, Gilead Licenses HPI Program, Raises $166M, Faces HBV Program Setback

summarizeSummary

Assembly Biosciences reported a significantly reduced net loss for 2025 and a strong cash position into 2028, driven by a $35 million payment from Gilead Sciences for licensing its HPI program. However, Gilead declined to license the HBV program, prompting Assembly Bio to seek new partners.

check_boxKey Events

• Significantly Reduced Net Loss

  Net loss decreased to $6.1 million in 2025 from $40.2 million in 2024, indicating improved financial performance.

• Gilead Licenses HPI Program

  Gilead Sciences exercised its option in December 2025 to exclusively license Assembly Bio's HPI program for recurrent genital herpes, triggering a $35 million payment and potential future milestones and royalties.

• Gilead Declines HBV Program

  In March 2026, Gilead declined its option for the ABI-4334 HBV program, leading Assembly Bio to seek new partners and not advance it independently.

• Substantial Capital Raise & Dilution

  The company raised $166.4 million net in August 2025 through an underwritten offering and a private placement with Gilead, significantly increasing shares outstanding by over 100% in 2025.

auto_awesomeAnalysis

This annual report highlights a pivotal year for Assembly Biosciences, marked by a substantial improvement in financial performance with a significantly reduced net loss. The licensing of the HPI program to Gilead, a major pharmaceutical partner, is a strong validation of Assembly Bio's pipeline and provides a significant non-dilutive cash infusion along with future revenue potential. However, the concurrent decision by Gilead to decline the HBV program is a notable setback, requiring the company to re-strategize for that asset. The company also executed a substantial capital raise in August 2025, which, while bolstering its cash reserves and extending its operational runway into 2028, resulted in significant shareholder dilution, with shares outstanding more than doubling in 2025. Investors should weigh the positive clinical and collaboration advancements against the dilution and the need to find a new partner for the HBV program.